Strategic partnerships Tempus is actively expanding collaborations with major pharma players like Bristol Myers Squibb, signaling a strong opportunity to pitch data licensing, AI-driven diagnostics, and multimodal oncology data services to large pharma accounts seeking integrated AI-enabled drug development support.

MRD and data moat The acquisition of Personalis to bolster MRD capabilities, combined with a growing data and applications backlog and FDA-aligned oncology data assets, presents a compelling case to offer targeted MRD testing, biomarker discovery, and diagnostic workflow integrations to oncology-focused customers.

AI-enabled revenue Tempus reports positive EBITDA trajectory, robust YoY revenue growth, and expanding AI-driven diagnostics channels, suggesting upsell opportunities for existing customers and potential cross-sell of AI platforms, data licenses, and operational analytics to pharma and clinical partners.

Strategic collaborations Partnerships like Pathos AI with Tempus to build specialized datasets and AI agents indicate a market demand for curated data ecosystems; this opens doors for enterprise customers seeking end-to-end data curation, model training, and integrated AI solutions in neurology and oncology.

Market differentiation Tempus emphasizes a data moat and differentiated models integrated into diagnostic workflows, presenting sales angles around secure data access, compliance, and seamless integration with existing clinical and R&D pipelines to hospitals, labs, and biopharma customers seeking faster time-to-insight.